logo

Eagle Pharmaceuticals Inc (EGRX)



Trade EGRX now with
  Date
  Headline
3/28/2022 2:43:52 AM Acacia Pharma, Eagle Pharma Agree Offer Terms
2/1/2022 6:57:13 AM Eagle Pharma Announces Commercial Availability Of PEMFEXY On Nonsquamous Non-small Cell Lung Cancer
1/31/2022 6:53:48 AM Eagle Pharma Says On Track To Support Submission Of Landiolol NDA In Q2 2022
1/18/2022 6:54:46 AM Eagle Pharma Announces Commercial Availability Of Vasopressin, A-rated Generic Alternative To Vasostrict
12/20/2021 12:15:41 PM Eagle Pharmaceuticals Reports That Par Has Unilaterally Withdrawn Attempt To Halt Launch Of Vasopressin
11/9/2021 7:07:41 AM Eagle Pharmaceuticals Q3 Loss/sjhr $0.43 Vs. EPS $0.51 Last Year
8/31/2021 11:51:08 AM Eagle Pharmaceuticals Wins Vasopressin Patent Trial
8/31/2021 6:56:16 AM Eagle Pharma Says U.S. Patent And Trademark Office Grants Additional Patent For Bendamustine Franchise
8/25/2021 6:56:36 AM Eagle Pharma Announces Licensing Deal With Combioxin For Phase 2b/3Development Of CAL02 With Antibiotics
8/9/2021 6:57:32 AM Eagle Pharma Q2 Net Income $3.6 Mln Or $0.27/Shr Vs Loss Of $0.3 Mln Or $0.02/shr Last Year
8/9/2021 6:51:29 AM Eagle Pharma Announces Licensing Agreement With AOP Orphan For U.S. Commercial Rights To Landiolol
6/24/2021 7:00:46 AM Eagle Pharma: FDA Maintains Priority Review For Vasopressin ANDA
6/17/2021 6:53:35 AM Eagle Pharma Submits Response To Complete Response Letter From FDA For Vasopressin
5/3/2021 6:53:26 AM Eagle Pharma Appoints Luciana Borio To Board
3/2/2021 6:55:01 AM Eagle Pharma Q4 Adj. Net Income $12.8 Mln Or $0.96/shr Vs. Income Of $6.7 Mln Or $0.48/shr Prior Year